Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-21-014578
Filing Date
2021-04-02
Accepted
2021-04-02 16:15:13
Documents
2
Period of Report
2021-03-23

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 2302
2 EX-24.1 DOCUMENT attachment1.htm EX-24.1 4607
  Complete submission text file 0000899243-21-014578.txt   8263
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Issuer) CIK: 0001680581 (see all company filings)

EIN.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O SEELOS THERAPEUTICS, INC. 300 PARK AVENUE, 12TH FLOOR NEW YORK NY 10022
Business Address
Dunn Judith (Reporting) CIK: 0001811904 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38978 | Film No.: 21802128